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Background. The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage
malaria vaccine FMP2.1/AS02A in adults exposed to seasonal malaria. Methodology/Principal Findings. A phase 1 double
blind randomized controlled dose escalation trial was conducted in Bandiagara, Mali, West Africa, a rural town with intense
seasonal transmission of Plasmodium falciparum malaria. The malaria vaccine FMP2.1/AS02A is a recombinant protein (FMP2.1)
based on apical membrane antigen-1 (AMA-1) from the 3D7 clone of P. falciparum, adjuvanted with AS02A. The comparator
vaccine was a cell-culture rabies virus vaccine (RabAvert). Sixty healthy, malaria-experienced adults aged 18–55 y were
recruited into 2 cohorts and randomized to receive either a half dose or full dose of the malaria vaccine (FMP2.1 25 mg/AS02A
0.25 mL or FMP2.1 50 mg/AS02A 0.5 mL) or rabies vaccine given in 3 doses at 0, 1 and 2 mo, and were followed for 1 y.
Solicited symptoms were assessed for 7 d and unsolicited symptoms for 30 d after each vaccination. Serious adverse events
were assessed throughout the study. Titers of anti-AMA-1 antibodies were measured by ELISA and P. falciparum growth
inhibition assays were performed on sera collected at pre- and post-vaccination time points. Transient local pain and swelling
were common and more frequent in both malaria vaccine dosage groups than in the comparator group. Anti-AMA-1 antibodies
increased significantly in both malaria vaccine groups, peaking at nearly 5-fold and more than 6-fold higher than baseline in
the half-dose and full-dose groups, respectively. Conclusion/Significance. The FMP2.1/AS02A vaccine had a good safety
profile, was well-tolerated, and was highly immunogenic in malaria-exposed adults. This malaria vaccine is being evaluated in
Phase 1 and 2 trials in children at this site. Trial Registration. ClinicalTrials.gov NCT00308061
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INTRODUCTION
Plasmodium falciparum malaria remains a major global killer,
especially of infants and children, and a serious threat to travelers.
A safe and effective malaria vaccine used in conjunction with other
control measures would be a huge boon to the health and
economies of malaria-endemic countries. In recent clinical trials,
RTS,S/AS02, a recombinant subunit protein malaria vaccine
designed to block infection, demonstrated 35% efficacy against
uncomplicated malaria and 49% efficacy against severe malaria
for at least 18 months in young children and 66% efficacy against
P. falciparum infection in infants [1–3]. Approaches to improve on
this efficacy include building multi-stage, multi-antigen vaccines
[4], combination with a viral vector [5] and developing more-
effective single antigen or live attenuated vaccines [6,7].
Apical membrane antigen-1 (AMA-1) is a 83-kilodalton surface
protein that is expressed by mature intra-erythrocytic malaria
parasites and processed to a 66-kilodalton protein before being
exported to the merozoite surface around the time of rupture of
the infected erythrocyte [8]. Several lines of evidence including in
vitro growth inhibition assays [9–12], antibody-mediated inhibi-
tion of antigen processing [13], and sero-epidemiological surveys
[14,15] support a critical role for AMA-1 during merozoite
invasion of erythrocytes. A vaccine that boosts levels of anti-AMA-
1 antibodies might therefore reduce the risk that malaria infection
will cause clinical disease.
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AMA-1 is highly polymorphic [16,17]. Polymorphisms in AMA-
1 allow the parasite to evade antibody-mediated inhibition of
invasion in vitro [18], and sera from rabbits immunized with
different forms of AMA-1 showed limited cross-protection, with
the level of inhibition inversely related to the number of amino
acid differences between parasite strains [12,19,20]. The rele-
vance, if any, of these in vitro and animal studies for allele-specific
efficacy of AMA-1 vaccines in humans is unknown. Presently three
AMA-1-based adjuvanted protein vaccines are being evaluated in
clinical trials in Mali, including two different monovalent vaccines
based on AMA-1 derived from the 3D7 and FVO clones of P.
falciparum, respectively, [20,21]and a bivalent vaccine that includes
both of these versions of AMA-1 [22].
Falciparum Malaria Protein 2.1 (FMP2.1) is a recombinant
AMA-1 from the 3D7 clone of P. falciparum that is produced in and
purified from Escherichia coli [23]. Together with the AS02A
adjuvant system, an oil-in-water emulsion with the immunostim-
ulants monophosphoryl lipid A and QS 21, it constitutes the
FMP2.1/AS02A malaria vaccine. This vaccine has been evaluated
in a Phase 1 dose escalation clinical trial in malaria-naive North
American adults [21]. The vaccine was well tolerated and strongly
immunogenic, inducing both humoral and cellular immune
responses. Vaccine-induced antibodies also inhibited parasite
growth and interfered with antigen processing in vitro. Because
previous exposure to malaria may affect the reactogenicity and
immunogenicity of malaria vaccines, we conducted a Phase 1 dose
escalation trial of this vaccine in malaria-experienced adults in
Mali. A cell-culture rabies virus vaccine was used as a comparator
to help distinguish vaccine-induced immune responses from
natural background immunity. This study was the first evaluation
of FMP2.1/AS02A in a malaria-experienced population and the
antecedent to Phase 1 and Phase 2 clinical trials of this vaccine in
children that are now in progress at this site.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Setting
The study was conducted at the Bandiagara Malaria Project
research clinic adjacent to the district hospital in Bandiagara, a
rural town of 13,634 inhabitants in the Dogon Country in
northeast Mali. It is relatively dry, with a mean annual rainfall of
600 mm. Anopheles gambiae is the principal malaria vector. Malaria
transmission is strictly seasonal, with virtually undetectable
transmission at the height of the dry season in March; less than
1 infected bite per person per month as the transmission season
starts and ends in June and December, respectively; and a peak of
up to 60 infected mosquito bites per person per month in August
or September [24,25]. P. falciparum represents 97% of malaria
infections with 3% due to P. malariae and rare infections with P.
ovale. Despite the seasonal transmission pattern the malaria burden
is heavy: children aged less then 10 years have an average of 2
clinical malaria episodes every transmission season [25] and severe
malaria afflicts 1 in 50 children aged less than 6 years each year
[24]. Older children and adults are relatively protected against
malaria disease but remain susceptible to malaria infection.
Participants
After obtaining community permission as described by Diallo et al.
[26], the trial was publicized by local radio broadcast. Men and
women aged 18 to 55 years were invited to the research clinic to
be screened for eligibility. Participants were included if they had
resided in Bandiagara for at least 12 months, gave written
informed consent, and, if female, declared their intent not to
become pregnant during the first 3 months of the study (up to one
month following the third immunization). Exclusion criteria
included: current illness as indicated by history, examination
and/or laboratory testing, previous immunization with a rabies
vaccine or any experimental vaccine, recent use of immunosup-
pressants, receipt of blood products during the previous 6 months,
pregnancy or breast-feeding, alcohol or drug abuse, and allergy to
substances present in the vaccines.
Ethical compliance The trial was conducted in compliance
with the International Conference on Harmonization Good
Clinical Practices, the Declaration of Helsinki and regulatory
requirements of Mali. The protocol was approved by institutional
review boards of the University of Bamako Faculty of Medicine,
University of Maryland Baltimore, and the U.S. Army Surgeon
General. Separate written informed consent was obtained for
screening and for enrollment. Consent of illiterate participants was
documented by their thumbprints and by signatures of
independent witnesses. Permission to import and administer the
investigational products in Mali was granted by the Republic of
Mali Ministry of Health. The trial was monitored by the United
States Army Medical Materiel Development Activity and the
National Institute of Allergy and Infectious Diseases/Division of
Microbiology and Infectious Diseases.
Interventions
The FMP2.1 antigen (Lot 0971) is comprised of amino acids #83-
531 corresponding to the ectodomain of AMA-1 derived from the
3D7 clone of P. falciparum. The protein was produced in and
purified from E. coli bacteria under current Good Manufacturing
Practices at the Walter Reed Army Institute of Research Pilot
Bioproduction facility (Forest Glen, Maryland, United States) [23].
The vaccine was provided in vials containing approximately 50 mg
of lyophilized protein.
The AS02A adjuvant system is composed of an oil-in-water
emulsion and two immuno-stimulants, 3-deacylated monopho-
sphoryl lipid A and QS21, a saponin agent derived from the soap
bark tree, Quillaja saponaria [27,28]. AS02A was manufactured by
GlaxoSmithKline Biologicals (Rixensart, Belgium) according to
current Good Manufacturing Practices P and provided in pre-
filled syringes. The whole content of each FMP2.1 vial was
dissolved in the whole content of a separate 0.62 mL vial of
AS02A immediately before injection. The RabAvert rabies
vaccine (Chiron Corporation, Emeryville, California, United
States) is a sterile freeze-dried vaccine obtained by growing the
fixed-virus strain Flury LEP in primary cultures of chicken
fibroblasts. It is supplied in pre-filled syringes containing
lyophilized antigen to which 1 mL of sterile water was added as
a diluent before injection. All vaccines were administered by
intramuscular injection in the left deltoid muscle.
Sixty adults were sequentially assigned to 2 cohorts of 30.
Within each cohort, participants were randomized in a 2:1 fashion
to receive FMP2.1/AS02A or rabies vaccine. After reconstitution,
the dose of FMP2.1/AS02A was approximately 25 mg of FMP2.1
in a final volume of 0.25 mL AS02A in Cohort 1 (half dose), and
approximately 50 mg FMP2.1 in a final volume of 0.5 mL in
Cohort 2 (full dose). Vaccines were given on a 0-, 1- and 2-mo
schedule. The first vaccination was given in early December 2004
at the end of the malaria transmission season; the second and the
third doses were given in January and February 2005, when
virtually no malaria transmission occurs at this site. Study day 90
was in March 2005, at the nadir of malaria transmission, study day
AMA-1 Malaria Vaccine Trial
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180 was at the beginning of the malaria season, and study day 272
was in September, at the peak of malaria transmission intensity.
The final study follow-up on day 364 coincided with the end of the
2005 malaria season. The cohorts were immunized in a staggered
fashion to permit interim safety analyses; each successive
immunization of Cohort 1 was followed in approximately 3 wk
by the corresponding immunization of Cohort 2. Three interim
safety analyses were reviewed by an independent Safety Monitor-
ing Committee, which provided written recommendations to
proceed before each of the three immunizations of Cohort 2 with
the full dose of FMP2.1/AS02A.
Objectives
The primary objective was to evaluate the safety and reactogenicity
of 3 injections of 2 different dose levels of the malaria vaccine
FMP2.1/AS02A in malaria-experienced Malian adults. Secondary
objectives were to measure the magnitude and duration of antibody
responses to FMP2.1, and exploratory objectives included measuring
vaccine-induced cellular immune responses at baseline and after
immunization (results to be presented elsewhere); and measuring the
inhibition of parasite growth by in vitro growth inhibition assays.
Outcomes
The primary outcome was safety, measured as 1) occurrence of
solicited symptoms during an 8-day follow-up period after
immunization (day of immunization and days 1, 2, 3 and 7 after
immunization); 2) occurrence of unsolicited symptoms during a
31-day follow-up period after immunization (day of immunization
and 30 subsequent days); 3) occurrence of laboratory toxicities
during the study period; and 4) occurrence of serious adverse
events during the study period. Secondary outcomes were anti-
AMA-1 antibody titers measured against recombinant 3D7 AMA-
1 and at baseline and at specified times during and after
immunization. Serum inhibition of parasite growth in vitro was
an exploratory outcome.
Assessment of safety and tolerability Following each
immunization, participants were directly observed for
30 minutes, then evaluated at the study clinic 1, 2, 3, 7 and 14
days after each immunization and on study days 90, 180, 272 and
364. Starting on day 120, monthly home visits were made to check
the health status of participants and to encourage them to come to
the research clinic if they felt ill. Study physicians were available at
the research clinic at all times throughout the 12-month study to
assess and treat adverse events.
Clinical evaluations consisted of measurement of vital signs and
assessment for local injection site and general solicited signs or
symptoms. Local signs and solicited symptoms included pain,
swelling, erythema at the injection site and limitation of arm
abduction at the shoulder. General signs and solicited symptoms
included fever (oral temperature$37.5uC), chills, nausea, headache,
malaise, myalgia and joint pain. Any other signs or symptoms were
considered to be unsolicited, as were all signs or symptoms that
occurred more than 7 days after immunization. Solicited symptoms
were considered to be related to the study vaccines. Unsolicited signs
and symptoms were recorded during the 30 days after each
immunization, whereas serious adverse events and pregnancies were
monitored throughout the 12-month study.
Blood was collected at screening, on immunization days, 7 and
14 days after each immunization and on study days 90, 180, 272
and 364 to determine complete blood count, alanine aminotrans-
ferase (ALT) and serum creatinine.
Adverse events were graded by severity and judged for relatedness
to study vaccines. Grade 1 adverse events were easily tolerated,
causing minimal discomfort and not interfering with daily activities.
Grade 2 adverse events were sufficiently discomforting to interfere
with normal activities. Grade 3 adverse events prevented normal
daily activities. Swelling, erythema, fever and limitation of arm
motion had specific definitions not based on interference with daily
activities. Injection site swelling and erythema were graded based on
their widest dimension: Grade 1, .0 to 20 mm; Grade 2, .20 to
50 mm; and Grade 3, .50 mm. Fever was classified as Grade 3 if
the oral temperature was$39uC whereas Grade 3 limitation of arm
motion was classified as abduction limited to 30u. For laboratory
tests, toxicity grading was adapted to normal reference ranges
determined for the local adult population.
Antibody responses to AMA-1 Antibody responses to AMA-1
were measured by an enzyme-linked immunosorbent assay (ELISA)
[21,21]. Briefly, IgG ELISAs were performed using FMP2.1 as the
capture antigen, in serial 2-fold dilution, and the titer was defined as
the serum dilution required to yield and optical density of 1.0 in our
assay. Antibody responses were measured on serum obtained from
participants at the time of each immunization (study days 0
[baseline], 30 and 60), 2 wk after each immunization (study days
14, 44 and 74), and 1, 3, 6 and 10 mo after the scheduled time of the
last immunization (study days 90, 180, 272 and 364).
Growth invasion/inhibition assay Pre-immunization (day 0)
sera and sera from 2 wk after the third immunization (day 74,
corresponding to peak antibody titers) were tested for growth
inhibitory effects against homologous (derived from 3D7 clone) and
heterologous (derived from FVO clone) P. falciparum parasites as
described [21,29]. Sera were dialyzed using 12–14 kilodalton
molecular weight cutoff membranes against three rounds of 16
PBS and one round of RPMI 1640 [30]. Samples were then heat-
inactivated for 20 min at 56uC and pre-absorbed with erythrocytes
from the same donor as the erythrocytes in which parasites had been
cultured (2.5 ml of erythrocytes at 50% hematocrit for 50 ml serum).
Samples were tested at 20% serum concentration in 384-well plates
(Perkin Elmer Spectra 384-TC plates, Cat #6007650) against 3D7
or FVO parasites (2% hematocrit, 0.3% starting parasitemia). Assays
were initiated with parasites synchronized at schizont stage and
harvested 40 hrs (3D7) or 44 hrs (FVO) after culture setup, i.e., after
one cycle. Growth inhibition was determined by measuring parasite
lactate dehydrogenase as described [19] and reported as percent
growth inhibition relative to control. Growth inhibition assays were
performed in a double blind manner.
Detailed methods and results of assays for cellular immune
responses will be described in a separate publication.
Sample size
A sample size of 20 in each group was chosen to balance the need to
detect any possible untoward reactions against the need to limit the
number of volunteers involved for safety purposes. This Phase 1 trial
was thus not powered to detect differences between groups and
where comparative statistics for the safety variables were computed,
the study had power to detect only large differences in the incidence
of local and general side effects between the vaccination groups.
Incorporation of a comparator vaccine group of 20 permitted broad
initial estimates of the incidence of local and general side effects and
of immune responses among vaccine recipients.
Randomization—Sequence generation
Within the two cohorts, individual participants were randomized
in a 2:1 ratio to receive either FMP2.1/AS02A (half dose in
Cohort 1 and full dose in Cohort 2) or rabies vaccine. The
randomization sequence was generated by a computer program
using blocks of three to ensure a 2:1 ratio of vaccine allocation.
AMA-1 Malaria Vaccine Trial
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Randomly generated sequential codes linked each study number
to a vaccine assignment (FMP2.1/AS02A or rabies vaccine).
Randomization—Allocation concealment
The randomization sequence was provided by the study
statistician consultant in an opaque sealed envelope to the study
pharmacists. In addition the local safety monitor was provided
with a sealed envelope to be opened if it was deemed necessary to
determine urgently the intervention a participant had received; no
such emergency unblinding occurred. The only people at the study
site with access to the randomization codes during the study were
2 study pharmacists, who had no contact with study participants
and did not reveal vaccine assignments to anyone else. Study
participants and investigators who assessed outcomes were blinded
to vaccine assignment.
Randomization—Implementation
Clinical investigators assigned study numbers to participants of
each group in the order in which they arrived at the clinic on the
first day of immunization. At the time of the first immunization,
study pharmacists opened the sealed envelopes containing the
vaccine assignment and prepared the vaccine to be administered
to the respective study participant. The vaccine and dose assigned
during the first immunization were maintained for second and
third immunizations. The study pharmacists prepared the vaccines
in a special room with access strictly limited to them and to study
monitors. Syringes containing the prepared vaccines were passed
through small sliding doors from the vaccine preparation room to
separate vaccine administration rooms, where the immunizations
were administered.
Blinding
The reconstituted rabies vaccine was a clear to slightly opaque,
colorless suspension of 1 mL volume, while FMP2.1/AS02A was
off-white and either 0.25 or 0.5 mL in volume. Syringes
containing vaccines were covered with opaque tape to conceal
their content from participants and immunizers. The study
pharmacists, who were unblinded, had no study-related contact
with participants and were not involved in outcome assessment.
Because of the difference in volumes, the immunizers could
potentially have deduced which vaccine was given to a specific
participant, and therefore they did not participate in other study
procedures. The presence of both study pharmacists and
immunizers at the site was limited to the periods during which
immunizations were given, and these individuals were instructed
not to discuss vaccine allocation with other study staff.
Statistical methods
Adverse event rates were analyzed using SPSS version 11.1 (SPSS,
Chicago, Illinois, United States). Fisher’s exact test was used to
compare rates between vaccine groups. Confidence intervals for
geometric mean AMA-1 antibody titers were estimated by using
log10-transformed values, calculating the 95% confidence interval
based on the normal distribution, and then converting the limits to
the original scale for presentation. Wilcoxon Signed Rank Test
was used to evaluate vaccine effects on parasite growth inhibition
on paired samples from study days 0 and 74, for each study group.
The differences in mean parasite growth inhibition for the three
study groups on study day 74 was evaluated by using a One Way
ANOVA and adjusted for multiple comparisons using Tukey’s
post test on pairwise comparisons using Jandel SigmaStat version
2.0 (Corte Madera, CA, United States). For longitudinal analysis
of antibody responses, log-transformed antibody titers were
modeled using mixed spline models to determine the effect of
vaccine dose on mean antibody levels over time using SAS version
9.1 (Cary, NC, United States). The spline models consisted of a
linear function joined to a quadratic function at study day 74. A
spatial exponential covariance structure was used to model the
correlation between measurements from the same individual
taking into account the number of study days between each
measurement. Point estimates and confidence intervals for each
time point were generated based on the fitted longitudinal model,
using the ESTIMATE statement in the MIXED procedure in
SAS. All tests were 2-sided, and no correction of p-values was
made for additional analyses. Given the large number of statistical
tests performed and the small sample size, the p-values have
limited probabilistic interpretation. Safety and immunogenicity
analyses were based on intention-to-treat, such that all available
data were included in analyses including partial data from 2
participants who were subsequently lost to follow-up.
RESULTS
Participant flow
One hundred and seventy five persons were screened, and 60 who
fulfilled the criteria for inclusion were enrolled in the study
(Figure 1). The most common reasons for exclusion were medical
illnesses and planned travel out of the study area. After enrollment,
one participant traveled outside the study area two days after his
second immunization and missed all subsequent visits, and one
participant missed the final study visit on day 364 due to travel.
Three participants temporarily left the study area to attend a
professional meeting, and missed only their study day 63 clinic
visits. All of these participants received all 3 doses of vaccine. One
participant received only 2 immunizations due to an elevated ALT
(described below in Laboratory Safety Tests).
Recruitment
Participants were recruited from November 19 to December 2,
2004. Immunizations for Cohort 1 began on December 4, 2004 and
for Cohort 2 on December 24, 2004. Subsequent immunizations
were done at 30-day intervals following this staggered start. Active
surveillance of participants for 30 days after each immunization was
completed in March 2005, corresponding to study day 90. The
database was locked for the primary unblinded analysis after study
day 90, and the study continued in a single-blinded fashion, although
individual study allocations were not disclosed to on-site study
investigators or staff with the exception of the principal investigator.
The extended surveillance phase included continuous access to free
basic medical care at the research clinic, monthly home visits, and
scheduled visits on study days 180, 272 and 364.
Baseline data
The three study groups did not differ significantly at enrollment
with regard to sex, age or laboratory parameters (Table 1). Eleven
of 60 participants were female. The mean age was 28 y.
Numbers analyzed
All available data from all participants, including partial data from
participants lost to follow-up, were included in both safety and
immunogenicity analyses.
Safety and reactogenicity
Local solicited adverse events After each immunization, the
proportion of participants who had at least one local injection site
reaction during the 8-d post-immunization periods was higher and
AMA-1 Malaria Vaccine Trial
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Table 1. Baseline Characteristics of FMP2.1/AS02A and Rabies Vaccine groups
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristics FMP2.1/AS02A Half dose (n = 20) FMP2.1/AS02A Full dose (n = 20) Rabies Vaccine (n = 20)
Mean age in year (SD) 26.1 (9.2) 29 (11.2) 30.1 (12.2)
Number of Females 4 4 3
Mean WBC6103/mL (SD) 5.4 (1.3) 5.9 (2.2) 6.0 (1.5)
Mean hemoglobin g/dL (SD) 14.4 (1.4) 14.1 (1.6) 14.0 (1.6)
Mean platelets6103/mL (SD) 232.2 (61.3) 252.3 (81.3) 239.3 (68.2)
Mean lymphocytes6103/mL (SD) 1.9 (0.6) 2.3 (0.9) 2.2 (0.8)
Mean creatinine mM/L (SD) 77.8 (14.0) 77.1 (18.6) 76.6 (13.4)
Mean ALT U/L (SD) 18.0 (6.6) 17.3 (7.9) 18.1 (5.7)
GMT Anti-AMA-1 antibody titer (95% CI) 19,161 (8,570–42,844) 23,500 (9,079–60,826) 14,355 (5,860–35,165)
GMT, geometric mean titer; CI, confidence interval; ALT, alanine amino-transferase; SD, standard deviation.
doi:10.1371/journal.pone.0001465.t001..
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Figure 1. Trial Profile.
doi:10.1371/journal.pone.0001465.g001
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similar in both malaria vaccine groups, compared to the rabies
vaccine group (Table 2). Pain and swelling at the injection site
were the most common local reactions for all groups and tended to
diminish in frequency and severity with successive immunizations.
Grade 3 injection site swelling was seen after all immunizations in
all three groups, but was much more common in the FMP2.1/
AS02A malaria vaccine full-dose group. Swelling classified as
Grade 3 occurred in seven participants after each of the three
immunizations in that group, compared to one, three and two
participants after the first, second and third immunizations,
respectively, in the malaria vaccine half-dose group, and in one,
three and one participants after the first, second and third
immunizations, respectively, in the rabies vaccine group (Table 2).
The swelling was typically unnoticed by the participant and
detected only on physical examination, and did not interfere with
normal daily activities. No other Grade 3 local adverse events
occurred. Three episodes of Grade 1 arm motion limitation
occurred in the malaria vaccine full-dose group, one after the first
immunization and two after the second immunization. Five
episodes of arm motion limitation (four Grade 1, one Grade 2)
occurred in the malaria vaccine half-dose group, four after the first
immunization and one after the second immunization. No
episodes of arm motion limitation occurred in the rabies vaccine
group. All local solicited symptoms resolved without sequelae
during the 8-day post-immunization periods.
General solicited adverse events The malaria vaccine full-
dose group had the most general solicited signs and symptoms
during the 8-d post-immunization periods, with 14, 15 and 10
general adverse events following the first, second and third
immunizations, respectively, compared to 18, 4 and 6 in the half-
dose group and 2, 14 and 3 in the rabies vaccine group (Table 2).
Headache was the most common general adverse event in all
groups, followed by myalgia and malaise. All general solicited
adverse events were of Grade 1 or Grade 2 intensity and resolved
during the 8-day follow-up period.
Unsolicited adverse events Overall, unsolicited adverse
events reported during the 31-d post immunization periods were
balanced by group, with 109, 109 and 100 events reported for the
malaria vaccine full-dose group, half-dose group and rabies vaccine
group, respectively. The most frequent unsolicited adverse events
were upper respiratory tract infections and headaches, followed by
traumatic injuries, infections and other common medical problems.
All unsolicited adverse events were of Grade 1 or Grade 2 intensity
and all resolved during the study period.
One female participant in the rabies vaccine group had a
positive urine pregnancy test on study day 180. She subsequently
reported that she had terminated the pregnancy by elective
abortion. On study day 364, the last day of the study follow-up,
her pregnancy test was again positive. She later reported that this
pregnancy had also been terminated by elective abortion and that
she was in good health.
A second participant in the rabies vaccine group had a positive
pregnancy test on study day 90 and gave birth to a healthy male
child on study day 289. The parents later reported that the child
had died at home at one year of age of an undiagnosed illness that
was thought to be consistent with tetanus or meningitis.
Serious adverse events No serious adverse events occurred
during the study.
Laboratory safety tests Grade 1 elevated serum creatinine
levels were detected in six participants during the study: One
female in the rabies vaccine group had Grade 1 creatinine
elevations on study days 90, 272 and 364; one male in the rabies
group had a Grade 1 elevation on day 7 that persisted through day
363; a female in the malaria vaccine half-dose group and two
males in the full-dose group had Grade 1 elevations on study day 0
that either persisted or rose and fell above the upper limit of
normal, and remained at Grade 1 on day 364; and one male in the
full-dose group had a Grade 1 creatinine elevation only on day
364. These creatinine elevations never increased above Grade 1
and were not associated with clinical abnormalities.
Five participants (two each in the malaria vaccine half-dose and
full-dose groups and one in the rabies vaccine group) had Grade 1
elevated ALT levels, and one participant in the malaria vaccine full-
dose group had an ALT of 194 U/L on study day 30, prior to
immunization. This initial elevation was followed by a rise to 564 U/
L on study day 44 and then a decline to 13 U/L by day 60. Extensive
investigation including serological tests for hepatitis A, B and C
identified no cause for this elevated ALT with the exception of self-
administration of a single dose of 150 mg of diclofenac, a non-
steroidal anti-inflammatory drug with reported rare liver toxicity.
Hemoglobin levels remained within or slightly above the normal
range for all participants throughout the study (11.7 to 17.3 g/dL
for males; 10.0 to 14.4 g/dL for females). Grade 1 abnormalities in
white blood cell counts were infrequent and balanced by group.
Grade 3 low platelet counts were reported for two participants in
the malaria vaccine high dose group, but these were unaccom-
panied by any clinical signs and were determined to be false
positive results from an automated cell counter caused by platelet
aggregation, based on microscopic examination of the blood.
Immunogenicity
Baseline antibody titers were high in all groups (Figure 2),
reflecting a high level of naturally acquired immunity at the end of
the malaria transmission season. In contrast to the waning
antibody titers seen in the rabies vaccine comparator group
following the end of the malaria season, immunization with both
the half dose and full dose of the malaria vaccine was followed by
significant elevations in anti-AMA-1 antibodies. Antibody titers
peaked two weeks after the third immunization (study day 74),
with a 4.7-fold rise relative to baseline in the malaria vaccine half-
dose group and a 6.4-fold rise in the full-dose group. Mean AMA-
1 antibody levels remained higher in the malaria vaccine groups
than in the comparator group throughout the study period,
although confidence intervals for point-wise comparisons over-
lapped at study time points after day 90. Mean antibody titers
were higher in the full-dose group than in the half-dose group at all
time points, although these differences were not statistically
significant for point-wise comparisons.
Based on the fitted longitudinal model, participants who
received a full dose of the malaria vaccine had a significantly
greater mean antibody response at all time points from day 30 (one
month after the first immunization) through day 364 (the end of
the follow-up period) compared to those receiving the comparator
vaccine, and those receiving a half dose of the malaria vaccine had
a significantly greater mean antibody response at times points from
day 44 through day 272 compared to those receiving the
comparator vaccine. A dose-response antibody effect was
suggested by higher mean antibody responses in the full-dose
malaria vaccine group compared to half-dose group, with these
differences approaching but not reaching significance at study days
74, 90, and 180 (p = 0.050, 0.053, and 0.079, respectively).
Ancillary analyses
Growth inhibition assays Measurement of functional anti-
AMA1 antibodies in the sera from FMP2.1/AS02A-immunized
participants was quantified by determining the levels of parasite
lactate dehydrogenase as a biomarker for parasite viability in
AMA-1 Malaria Vaccine Trial
PLoS ONE | www.plosone.org 6 January 2008 | Issue 1 | e1465
T
a
b
le
2
.
Si
g
n
s
an
d
So
lic
it
e
d
Sy
m
p
to
m
s
d
u
ri
n
g
th
e
8
-d
Fo
llo
w
-U
p
P
e
ri
o
d
s
af
te
r
Ea
ch
Im
m
u
n
iz
at
io
n
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
F
M
P
2
.1
/A
S
0
2
A
h
a
lf
d
o
se
F
M
P
2
.1
/A
S
0
2
A
fu
ll
d
o
se
R
a
b
ie
s
V
a
cc
in
e
Im
m
u
n
iz
a
ti
o
n
1
( n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
2
(n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
3
(n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
1
(n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
2
(n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
3
(n
=
1
9
)
Im
m
u
n
iz
a
ti
o
n
1
(n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
2
(n
=
2
0
)
Im
m
u
n
iz
a
ti
o
n
3
(n
=
2
0
)
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
O
v
e
ra
ll
G
ra
d
e
3
Lo
ca
l
P
ai
n
(%
)
1
9
(9
5
)
0
1
5
(7
5
)
0
1
1
(5
5
)
0
2
0
(1
0
0
)
0
1
9
(9
5
)
0
1
4
(7
3
.7
)
0
6
(3
0
)
0
1
0
(5
0
)
0
6
(3
0
)
0
Sw
e
lli
n
g
(%
)
1
3
(6
5
)
1
(5
)
1
1
(5
5
)
3
(1
5
)
7
(3
5
)
2
(1
0
)
1
3
(6
5
)
7
(3
5
)
1
0
(5
0
)
7
(3
5
)
8
(4
2
.1
)
7
(3
5
)
3
(1
5
)
1
(5
)
3
(1
5
)
3
(1
5
)
4
(2
0
)
1
(5
)
Li
m
it
at
io
n
o
f
ar
m
m
o
ti
o
n
(%
)
4
(2
0
)
0
1
(5
)
0
0
0
1
(5
)
0
2
(1
0
)
0
0
0
0
0
0
0
0
0
Er
yt
h
e
m
a
(%
)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
G
e
n
e
ra
l
Fe
ve
r
(%
)
3
(1
5
)
0
1
(5
)
0
2
(1
0
)
0
2
(1
0
)
0
1
(5
)
0
3
(1
5
.7
)
0
0
0
1
(5
)
0
0
0
H
e
ad
ac
h
e
(%
)
5
(2
5
)
0
1
(5
)
0
1
(5
)
0
5
(2
5
)
0
8
(4
0
)
0
4
(2
1
)
0
2
(1
0
)
0
4
(2
0
)
0
3
(1
5
)
0
Jo
in
t
p
ai
n
(%
)
0
0
0
0
0
0
1
(5
)
0
1
(5
)
0
0
0
0
0
1
(5
)
0
0
0
M
ya
lg
ia
(%
)
2
(1
0
)
0
0
0
1
(5
)
0
3
(1
5
)
0
1
(5
)
0
2
(1
0
.5
)
0
0
0
3
(1
5
)
0
0
0
M
al
ai
se
(%
)
3
(1
5
)
0
0
0
1
(5
)
0
2
(1
0
)
0
2
(1
0
)
0
1
(5
.3
)
0
0
0
3
(1
5
)
0
0
0
N
au
se
a
(%
)
2
(1
0
)
0
1
(5
)
0
1
(5
)
0
0
0
1
(5
)
0
0
0
0
0
1
(5
)
0
0
0
C
h
ill
s
(%
)
3
(1
5
)
0
1
(5
)
0
0
0
1
(5
)
0
1
(5
)
0
0
0
0
0
1
(5
)
0
0
0
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
0
1
4
6
5
.t
0
0
2
.................................................................................
AMA-1 Malaria Vaccine Trial
PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1465
continuous erythrocyte cultures of synchronized P. falciparum
parasites. Sera from pre-immunization (day 0) and post
immunization (day 74, 2 wk after the third immunization) time-
points were tested against both the vaccine-homologous parasite
clone, 3D7 (Figure 3A), and against the heterologous clone, FVO
(Figure 3B). The immune sera generally gave higher growth
inhibition activity against the FVO clone of P. falciparum than
against the 3D7 clone. There was no difference in mean inhibition
of either 3D7 or FVO parasites between day 0 and day 74 in the
half-dose group (Wilcoxon Signed Rank Test analyses on paired
serum samples; p = 0.490 and 0.156, respectively). Inhibitory
activity at day 74 in the malaria vaccine full-dose group was
however significantly higher than the day 0 inhibition for this
group, against both the 3D7 and FVO clones (p = 0.024 and
p = 0.004, respectively). Sera from participants in the rabies
vaccine control group exhibited a significant increase in parasite
inhibitory activity against the FVO parasites, p = 0.048, but not for
the 3D7 parasites (p = 0.231). Comparison of mean inhibition on
day 74 for all groups suggested that while there was no difference
in growth inhibition between the rabies vaccine comparator group
and malaria vaccine half-dose groups, post-immunization sera
from participants who received the full dose of the malaria vaccine
had significantly greater growth inhibition activity against both
3D7 and FVO parasites than did post-immunization sera from
rabies comparator group (ANOVA p = 0.007 and p = 0.002,
respectively; Tukey post test; p,0.05). Compared to baseline,
growth inhibition activity against 3D7 tended to decrease
following immunization with the rabies vaccine and increase
following immunization with either dose of malaria vaccine,
although these trends were not statistically significant (Figure 3A).
DISCUSSION
Interpretation
This is the first evaluation of the AMA-1-based malaria vaccine
FMP2.1/AS02A in a malaria-experienced population. Both the
full dose and a half dose of the malaria vaccine had acceptable
tolerability. Local reactions were more frequent in both malaria
vaccine groups than in the comparator group. Pain and/or
swelling at the injection site were experienced by most recipients of
the malaria vaccine. Although swelling was often classified as
Grade 3 based on the size of the reaction (.50 mm), these
episodes of swelling were short-lived and were usually unnoticed
by participants. No participants were withdrawn from the study
because of adverse events with the exception of one individual who
had a transient high elevation of ALT temporally related to
immunization but thought likely to be due to ingestion of a drug
with known liver toxicity. No serious adverse events were
observed. Three pregnancies occurred, one resulting in a healthy
male child who died at the age of one year of an undiagnosed
illness thought to be consistent with tetanus, and two in one
participant that were terminated by elective abortion.
The malaria vaccine elicited high levels of antibodies recogniz-
ing the vaccine antigen. Differences in antibody levels between the
two malaria vaccine groups, and between malaria vaccine and
rabies vaccine comparator groups at time points 4 mo or longer
after the last immunization, were not statistically significant when
analyzed using point-wise comparisons. However, longitudinal
analyses demonstrated that the malaria vaccine full-dose group
had significantly higher antibody responses than the rabies vaccine
comparator group from 1 mo after the first immunization through
Figure 2. Anti-AMA-1 antibody titers. Geometric mean antibody titers to homologous recombinant AMA-1 for FMP2.1/AS02A full dose, FMP2.1/
AS02A half dose and rabies vaccine recipients. Times of each of three immunizations and the start and end of the malaria transmission season are
indicated by triangles. Error bars represent 95 percent confidence intervals.
doi:10.1371/journal.pone.0001465.g002
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the end of the 1 y study period, and the malaria vaccine half-dose
group had higher antibody responses than the comparator group
from 2 wk after the second immunization through 7 mo after the
third immunization. Longitudinal analyses also suggested a dose-
related antibody response with a trend toward higher responses in
the full-dose group compared to the half-dose malaria vaccine
group. Moreover, post-immunization sera from the full-dose
group, but not the half-dose group, had significantly greater
growth inhibition activity than sera from the comparator group
against both homologous and heterologous parasites. Based on
these data, the more immunogenic full dose of the vaccine
(FMP2.1 50 mg in 0.5 mL AS02A) was selected for further clinical
development. This vaccine is presently undergoing evaluation in
Phase 1 and 2 clinical trials in children at this site.
Generalizability
The safety and tolerability profile of the FMP2.1/AS02A vaccine
was similar to that seen in a previous trial of this vaccine in North
American malaria-naı¨ve volunteers [21] and in trials of a similar
recombinant protein blood-stage malaria vaccine with the same
adjuvant in this and other African populations [31,32].
While baseline antibody titers of AMA-1 antibodies were higher
in this malaria-experienced population than in malaria-naı¨ve
North American volunteers [21], post-immunization titers were of
a similar magnitude. Although antibody responses in a recent
Phase 1 trial of another AMA-1 vaccine using Alhydrogel as an
adjuvant [22] were measured using different methods than those
used to measure responses to FMP2.1/AS02A, the FMP2.1/
Figure 3. Growth inhibition assays. Mean percent growth inhibition of pre- and post-immunization sera against the 3D7 (A) and FVO (B) clones of
Plasmodium falciparum grown in vitro. Error bars represent 95 percent confidence intervals.
doi:10.1371/journal.pone.0001465.g003
AMA-1 Malaria Vaccine Trial
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AS02A vaccine induced more uniformly robust responses (with
100% of malaria-naı¨ve and malaria-experienced vaccine recipients
showing an increase in antibody titer), possibly due to use of the more
potent adjuvant system. In addition to inducing high ELISA activity,
the antibodies to FMP2.1/AS02A vaccine induced a moderate level
of growth inhibitory activity against parasites expressing both
homologous and heterologous AMA-1 [21]. Although a higher
degree of background growth inhibition was observed using sera
from malaria-experienced adults, immunization with 50 mg of
FMP2.1/AS02A induced measurably higher inhibitory antibodies
against both homologous and heterologous parasite strains than did
the 25 mg FMP2.1/AS02A dose. Interestingly, responses measured
against the FVO parasites were significantly higher than baseline at
the post third immunization sampling for the rabies controls,
suggesting a possible exposure during the study period to parasites
similar to FVO with respect to AMA-1 and/or other antigens
capable of stimulating allele-specific growth inhibition.
Although these results are promising, until a blood-stage
malaria vaccine demonstrates clinical efficacy, immune correlates
of vaccine-induced protection and the choice of immunogenicity
endpoints for clinical development decisions will remain a matter
of reasoned conjecture.
P. falciparum AMA-1 is extremely polymorphic, with more than
100 polymorphic amino acid sites, and in vitro experiments and
studies in both animals and humans have indicated some degree of
allele-specificity in the antibody responses to genetically different
forms of AMA-1 [12,17–21]. The FMP2.1/AS02A vaccine is based
on AMA-1 sequence from the 3D7 clone of P. falciparum. Other
AMA-1-based vaccines are being developed based on AMA-1
sequence from the FVO clone [20] and from both 3D7 and FVO
[22]. If immunity elicited by an AMA-1 vaccine is allele-specific,
then initial vaccine efficacy may depend on the degree of homology
at key amino acid residues between the vaccine antigen and AMA-1
in parasites circulating at vaccine trial sites. Moreover, vaccination
may result in directional selection favoring AMA-1 alleles that are
different from those targeted by the vaccine, resulting in reduced
efficacy over time. As this and other AMA-1-based vaccines progress
to trials measuring clinical efficacy, it will be important to measure
allele-specific efficacy and to identify which specific polymorphisms
or sets of polymorphisms are under selection by vaccine-induced
immune responses. In the likely event that the genetic diversity of
AMA-1 in natural populations of malaria parasites restricts the
efficacy of AMA-1 vaccines, it may be necessary to construct a
polyvalent and/or chimeric vaccine [33] based on detailed
molecular epidemiological and molecular evolutionary analyses of
vaccine efficacy and selection in early efficacy trials.
Overall evidence
Based on its good safety profile, acceptable tolerability, and robust
antibody responses, the AMA-1-based malaria vaccine FMP2.1/
AS02A is being evaluated in Phase 1 and Phase 2 clinical trials in
children aged 1–6 years at the Bandiagara Malaria Project in
Mali. If the results of these trials are promising, the development
pathway for this vaccine could include incorporating the FMP2.1
antigen as one component of a multi-stage, multi-antigen malaria
vaccine in combination with RTS,S [4], improved adjuvant
formulations [34] and/or separate development as a disease-
blocking vaccine for use in targeted populations in high malaria
transmission areas. As AMA-1 malaria vaccines move into efficacy
trials, the impact of genetic diversity on malaria vaccine efficacy is
likely to emerge as a critical problem requiring integration of
methods and concepts drawn from molecular epidemiology,
molecular evolution, immunology and structural vaccinology.
SUPPORTING INFORMATION
Checklist S1 CONSORT checklist
Found at: doi:10.1371/journal.pone.0001465.s001 (0.06 MB
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